Ansamitocin P-3 (Maytansinol isobutyrate; NSC-292222; Antibiotic C 15003P3) is a potent microtubule/antimitotic inhibitor used as an warhead of ADC (antibody drug conjugate). With high antiproliferative activity, ansamitocin P-3 is a macrocyclic antibiotic that fights cancer.
Physicochemical Properties
Molecular Formula | C32H43CLN2O9 |
Molecular Weight | 635.14482 |
Exact Mass | 634.265 |
Elemental Analysis | C, 60.51; H, 6.82; Cl, 5.58; N, 4.41; O, 22.67 |
CAS # | 66584-72-3 |
Related CAS # | 66547-09-9 (AP-3');66584-72-3 (AP-3); |
PubChem CID | 5282049 |
Appearance | White to off-white solidw powder |
Density | 1.3±0.1 g/cm3 |
Boiling Point | 833.1±65.0 °C at 760 mmHg |
Melting Point | 190-192℃ |
Flash Point | 457.7±34.3 °C |
Vapour Pressure | 0.0±3.2 mmHg at 25°C |
Index of Refraction | 1.583 |
LogP | 5.09 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 5 |
Heavy Atom Count | 44 |
Complexity | 1150 |
Defined Atom Stereocenter Count | 7 |
SMILES | ClC1=C(N(C)C(C[C@H](OC(C(C)C)=O)[C@@](O2)(C)[C@]2([H])[C@H](C)[C@]3([H])C[C@](NC(O3)=O)(O)[C@H](OC)/C=C/C=C(C)/C4)=O)C=C4C=C1OC |
InChi Key | OPQNCARIZFLNLF-JBHFWYGFSA-N |
InChi Code | InChI=1S/C32H43ClN2O9/c1-17(2)29(37)43-25-15-26(36)35(6)21-13-20(14-22(40-7)27(21)33)12-18(3)10-9-11-24(41-8)32(39)16-23(42-30(38)34-32)19(4)28-31(25,5)44-28/h9-11,13-14,17,19,23-25,28,39H,12,15-16H2,1-8H3,(H,34,38)/b11-9+,18-10+/t19-,23+,24-,25+,28+,31+,32+/m1/s1 |
Chemical Name | [(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate |
Synonyms | NSC292222; NSC-292222; NSC 292222; Maytansinol isobutyrate; Ansamitocin P-3; Maytansinoid AP-3 |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
Targets | Maytansinoids |
ln Vitro | Ansamitocin p-3, at a high concentration of 80 μM, does not cause tubulin to aggregation, in contrast to VCR, which totally inhibits the polymerization of tubulin isolated from bovine brains at 5 μM. Additionally, the polymerized tubulin is potently depolymerized by ansamitocin p-3 at 16 μM (IC50 = 3.8 μM). When culture cells are exposed to a specific concentration of dibutyryl cyclic adenosine 3':5'-monophosphate, the morphological change of AC cells from fibroepithelioid to glial cell type is prevented by the addition of ansamitocin p-3. Furthermore, the well-defined network of cytoplasmic microtubules in A31 cells rapidly disperses upon treatment with 16 nM ansamitocin p-3. Ansamitocin p-3 treatment for a brief period of time also prevents A31 or KB cells from synthesizing DNA. These findings demonstrate that ansamitocin p-3 inhibits mitotic spindle fiber formation and, ultimately, cytokilling by interfering with the microtubule assembly system. [1] Ansamitocin p-3 exhibits strong cytotoxicity in a dose-dependent manner against A-549, HT-29, and MCF-7 cells, with corresponding ED50 values of 4 ×10-7, 4 × 10-7, and 2 × 10-6 μg/mL. [2] Ansamitocin p-3 likewise demonstrates cytotoxicity with a significantly lower EC50 of 0.081 nM against HCT-116 cells. [3] In a p53-dependent manner, ansamitocin p-3 amplifies the effects of radiation in both human cancer cells and Drosophila cells.[4] |
ln Vivo | Ansamitocin P-3 treatment (>1 μg) causes an increased arrest in the metaphase of P388 leukemia cells and significantly suppresses the growth of leukemia SN36. Treatment with ansamitocin p-3 at a dose of 25 μg/kg/day considerably increases the survival period of mice with i.p. B16 melanoma by 130%. The treatment of mice with Ehrlich ascites carcinoma, Sarcoma 180, and P815 mastocytoma with ansamitocin p-3 also significantly extends their survival time; however, the treatment only marginally extends the survival time of mice with ascites MOPC-104E myeloma, leukemia L1210, and leukemia C1498.[1] |
Enzyme Assay | After adding 400 μL of bovine tubulin solution (1 mg/mL in cold MES buffer) and keeping it at 0 °C for 10 to 15 minutes, the mixture is warmed in a water bath at 37 °C for 30 to 60 minutes. Ansamitocin p-3 solution (GTP minus MES buffer) or 1 M Tris buffer, pH 8.4 (for blank) are added in various concentrations. As a result of the tubulin polymerization, the mixture becomes more turbid when it gets heated. It uses a Hitachi type 101 spectrophotometer to measure turbidity at 460 nm. |
Cell Assay | Following cell synchronization, different Ansamitocin p-3 concentrations are applied for approximately 24 hours. A volume of 1 mL is used to label cells with [3H]thymidine (5 Ci/mM, 1 μCi/mL). The cells on coverslips are fixed with a 3:1 ratio of methanol to acetic acid following an hour of pulse labeling at 37 °C. Each coverslip's radioactivity is measured using a liquid scintillation counter after the acidsoluble fraction has been removed from the cells. |
Animal Protocol |
Female DBA/2 mice bearing P388, L1210, or P815 cells, C57BL/6 mice bearing B16, or C1498 cells, ICR mice bearing sarcoma 180 and EAC, and BALB/c mice bearing MOPC-104E cells ~200 μg/kg Administered i.p. or i.v. daily |
References |
[1]. Cancer Res . 1980 May;40(5):1707-17. [1]. Experientia . 1990 Jan 15;46(1):117-20. [1]. J Biomol Screen . 2006 Feb;11(1):82-9. [1]. Dis Model Mech . 2011 Jul;4(4):496-503. [1]. PLoS One . 2013 Oct 4;8(10):e75182. |
Additional Infomation |
Ansamitocin P3 is a polyketide antibiotic that is isolated from Actinosynnema pretiosum and also exhibits antitumour activity. It has a role as an antimicrobial agent, a metabolite and an antineoplastic agent. It is a polyketide, a macrocycle, a lactam, an epoxide, a carboxylic ester, a carbamate ester, an aromatic ether and a member of monochlorobenzenes. Ansamitocin P-3 has been reported in Thamnobryum sandei, Isothecium subdiversiforme, and other organisms with data available. Ansamitomicin P-3 is an ansamacrolide and maytansine analogue originally isolated from the Ethiopian shrub Maytenus serrata with antineoplastic activity. Ansamitomicin P-3 binds to tubulin at the maytansine-binding site, thereby inhibiting microtubule assembly, inducing microtubule disassembly, and disrupting mitosis. |
Solubility Data
Solubility (In Vitro) |
DMSO: ~100 mg/mL (~157.5 mM) Ethanol: ~55 mg/mL (~86.6 mM) |
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (3.94 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (3.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.5745 mL | 7.8723 mL | 15.7446 mL | |
5 mM | 0.3149 mL | 1.5745 mL | 3.1489 mL | |
10 mM | 0.1574 mL | 0.7872 mL | 1.5745 mL |